Short communication on t(9;9)(p13;p24) PAX5/JAK2, with data on clinics, and the genes implicated.
Epidemiology
This chromosome abnormality has only been found so far in childhood B-ALL: there were 2 male and 2 female patients, aged 7, 10, 13 and 14 years.
Prognosis
Two of three patients were considered as being at high risk, and one at intermediate risk.
One patient was in complete remission (CR) 65 months after diagnosis, and another one was in a second CR at 10 months+ (Nebral et al., 2009 ).
Cytogenetics

Cytogenetics morphological
Additional chromosome abnormalities were noted in the two cases with complete data on the karyotypes. Phosphotyrosines are located at aa 119, 372, 373, 523, 813, 868, 966, 972, 1007 119, 372, 373, 523, 813, 868, 966, 972, , and 1008 119, 372, 373, 523, 813, 868, 966, 972, (Harpur et al., 1992 Saltzman et al., 1998; Lucet et al., 2006 Involved in B-cell differentiation. Entry of common lymphoid progenitors into the B cell lineage depends on E2A, EBF1, and PAX5; activates B-cell specific genes and repress genes involved in other lineage commitments. Activates the surface cell receptor CD19 and repress FLT3. Pax5 physically interacts with the RAG1/RAG2 complex, and removes the inhibitory signal of the lysine-9-methylated histone H3, and induces V-to-DJ rearrangements. Genes repressed by PAX5 expression in early B cells are restored in their function in mature B cells and plasma cells, and PAX5 repressed (Fuxa et al., 2004; Johnson et al., 2004; Zhang et al., 2006; Cobaleda et al., 2007; Medvedovic et al., 2011) .
Genes involved and proteins
JAK2
Result of the chromosomal anomaly
Hybrid gene
Description Fusion of PAX5 exon 5 to JAK2 exon 19 in each case. Opposite direction is noted by Coyaud et al., 2010 .
Fusion protein
Description 522 amino acids (201 from PAX5 and 321 from JAK2). The predicted fusion protein contains the DNA binding paired domain of PAX5 and the Protein kinase 2 domain from JAK2 (breakpoint at aa 811 or 812 in JAK2).
